Tumor-Associated Antigen Presentation by Dendritic Cells

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that play a central role in initiating and regulating anti-tumor immune responses. They are uniquely equipped to capture, process, and present tumor-associated antigens (TAAs) to T cells, thereby bridging innate and adaptive immunity. DCs can activate both CD4+ helper T cells via MHC class II presentation and CD8+ cytotoxic T lymphocytes through cross-presentation on MHC class I molecules. Effective presentation of TAAs by dendritic cells is essential for robust anti-tumor immunity. Dysfunctional or immature dendritic cell populations within tumors contribute significantly to immune evasion by suppressing effective anti-tumor responses.

Enhancing dendritic cell function, reprogramming endogenous dendritic cell populations, using ex vivo generated autologous dendritic cell vaccines, modulating innate immune signals that condition host dendritic cell activity, improving priming efficiency of anti-tumor effector T-cells